Skip to main content
OpenTrials
Completed

NCT Number: NCT05377515

Evaluation of Visual Outcomes in Patients With Complex Corneas Implanted With the IC-8 IOL

The purpose of this study is to evaluate visual outcomes in patients with complex corneas who have been previously implanted with the IC-8 IOL after cataract removal.

Completed

Looking for future studies?

Notify Me

Key information

Age range

22 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Singapore Eye Research Institute / Singapore National Eye Centre

Singapore

About this study

This will be a prospective, non-randomized, single-arm, single-visit, single-center, clinical study in up to 40 patients previously contralaterally implanted with the IC-8 IOL at one clinical site in Singapore.

The purpose of this study is to to evaluate visual outcomes in patients with complex corneas who have been previously implanted with the IC-8 IOL after cataract removal. The co-primary study endpoints are monocular uncorrected distance, intermediate, near visual acuities.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Minimum 22 years of age;
  • Able to comprehend and have signed a statement of informed consent;
  • Availability, willingness, ability and sufficient cognitive awareness to comply with examination procedures and study visit(s);
  • Having complex corneas prior to cataract surgery;
  • Previous cataract surgery and IC-8 IOL implantation in the eye (implanted for 3 months or longer prior to study participation).

Exclusion criteria

  • Baseline visual acuity worse than 20/25 BCDVA in either eye;
  • Presence of ocular abnormalities or conditions other than corneal irregularities that could confound the study outcome(s), such as:
  • Strabismus or amblyopia
  • Retinal or macular abnormalities
  • Recurrent and/or persistent ocular inflammation
  • Known pathology that may affect visual acuity to a level worse than 20/25 BCDVA
  • Previous intraocular surgery, except cataract surgery, pterygium surgery, or corneal procedures (other than corneal-cross linking);
  • Previous corneal cross-linking procedure with any corneal haze;
  • Conditions requiring planned ocular surgical intervention, except Nd:YAG capsulotomy;
  • Severe dry eye or other conditions (such as hormonal fluctuations) that could lead to unstable refraction and/or visual acuity measurements or eye discomfort even with ocular lubricants or dry eye medication;
  • Patient is pregnant or nursing.

Treatment and study plan

Primary outcomes

  1. Monocular UCDVA

    Time frame: 3 Months

    0.3 logMAR or better

  2. Monocular UCIVA

    Time frame: 3 Months

    0.3 logMAR or better

  3. Monocular UCNVA

    Time frame: 3 Months

    not worse than 0.3 logMAR

Sponsors and collaborators

Lead sponsor

AcuFocus, Inc.

Industry

Registry information

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
May 17, 2022
Registry last updated
May 10, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.